



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 30, 2010

To: Primary Clinical Research Associates

From: Sara Braun
Protocol Development Coordinator

Re: N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT)
Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

Attached are updated form(s) for this protocol. Edits are as follows:

CRF Title	Brief Description of Edit
Nadir/Adverse Event Form	<ul style="list-style-type: none">Added "CTCAE v3.0" to CTC Adverse Event Term on page 1 and 2
Baseline Adverse Events Form	<ul style="list-style-type: none">Added "CTCAE v3.0" to CTC Adverse Event Term

If you have any questions, please feel free to contact me.

Enclosure